May 1st 2024
The data will be presented in oral session at the 2024 American Society of Gene & Cell Therapy meeting May 7-11 in Baltimore, Maryland.
Ocugen, Inc. announces FDA clearance of IND amendment to Initiate OCU400 Phase 3 clinical trial
April 8th 2024According to the company, the Phase 3 study will have a sample size of 150 participants—one arm of 75 participants with the RHO gene mutation and the other arm with 75 participants that are gene agnostic.